Acquired Secondary RAS Mutation in BRAF(V600E)-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

Background: The BRAF(V600E) mutation is the most common driver mutation in papillary thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered actionable and, for BRAF(V600E)-mutated ATC, a BRAF inhibitor (dabrafenib) in combination with an MEK inhibitor (trametinib) is F...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thyroid
Autors principals: Cabanillas, Maria E., Dadu, Ramona, Iyer, Pryianka, Wanland, Kacey B., Busaidy, Naifa L., Ying, Anita, Gule-Monroe, Maria, Wang, Jennifer R., Zafereo, Mark, Hofmann, Marie-Claude
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc., publishers 2020
Matèries:
Thyroid Cancer and Nodules
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869871/
https://ncbi.nlm.nih.gov/pubmed/32216548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2019.0514
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars